CDH1 基因启动子甲基化与宫颈癌临床病理类型的关系

目的:探讨分析CDH1基因启动子甲基化与宫颈癌临床病理类型的关系。方法:选取2012年5月~2015年7月我院105例宫颈癌患者为宫颈癌组,同时选取60例正常宫颈组织为正常组,以甲基化特异性聚合酶链反应(MSP)检测CDH1基因启动子Cp G岛甲基化状态及高危型HPV DNA状态,分析CDH1基因甲基化状态与高危型HPV DNA状态及临床病理参数的关系。结果:宫颈癌组CDH1基因启动子甲基化阳性率为56.19%,明显高于正常组的6.67%,具有统计学差异(P0.05);宫颈癌组的高危型HPV DNA阳性率为84.76%,明显高于正常组的20.00%,具有统计学差异(P0.05);高危型HPV DNA与CDH1基因启动子甲基化的一致性分析结果具有统计学意义(P0.05);CDH1基因启动子甲基化率与患者的WHO组织分化程度分级、FIGO分期、组织病理学分型、肿瘤大小有关,差异有统计学意义(P0.05)。结论:宫颈癌CDH1基因启动子甲基化与WHO组织分化程度分级、FIGO分期、组织病理学分型、肿瘤大小具有关联,并与高危型HPV DNA阳性具有一致性,可以作为宫颈癌诊断和预后评估的参考指标。

The Relationship between CDH1 Gene Promoter Methylation and Clinical Pathological Types of Cervical Cancer

Objective:To explore the relationship between CDH1 gene promoter methylation and clinical pathological types of cervical cancer.Methods:105 cases of specimens from patients with cervical cancer (Cervical cancers group) and 60 cases of normal cervical (Normal controls group) were selected, then methylation specific polymerase chain reaction (MSP) was used to detect the CDH1 gene start promoter CpG island methylation status of the samples and the high-risk HPV DNA status. After that we analyzed the relationship between CDH1 gene methylation status and high-risk HPV DNA status, CDH1 gene methylation status and clinical parameters of patients.Results:The positive rate of CDH1 gene promoter methylation in cervical cancer group was 56.19%, significantly higher than that in the normal group (6.67%), with statistical difference (P<0.05). The positive rate of DNA HPV in cervical cancer group was 84.76%, which was significantly higher than that in the normal group (20%), and the difference was statistically significant (P<0.05). The consistency analysis results of DNA HPV and CDH1 gene promoter methylation were statistically significant (P<0.05). CDH1 gene promoter methylation rate was significantly associated with the degree of WHO differentiation, FIGO stage, histological grade, tumor size, which was statistically significant (P<0.05).Conclusion:The methylation of CDH1 gene promoter in cervical cancer is associated with many clinical parameters (WHO differentiation grade, FIGO grades, Histological types, Tumor diameter), and is consistent with the high risk type DNA HPV positive. It can be used as a reference index for the diagnosis and prognosis of cervical cancer.